Voyager Acquisition Corp./Cayman Islands (VACH)
Healthcare › Biological Products, (No Diagnostic Substances)
Price History
Feb 9, 2026 — Jun 23, 2026Investment Snapshot
- P/E of 58.0 — elevated valuation multiple
- Piotroski F-Score 2/9 — signs of financial weakness
- Loss-making — negative ROE of -36.4%
Voyager Acquisition Corp./Cayman Islands (VACH) is a Healthcare company operating in Biological Products, (No Diagnostic Substances), listed on the NASDAQ , with a market capitalisation of $433 million . Key value metrics: P/E ratio 58.0, Piotroski F-Score 2 out of 9 .
Value Score
Key Metrics
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Voyager Acquisition Corp./Cayman Islands — Fundamental Analysis Summary
Voyager Acquisition Corp./Cayman Islands (VACH) trades at a trailing P/E of 58.0x — 127% above the Healthcare sector average of 25.5x.
On financial health, VACH shows a weak Piotroski F-Score of 2/9, a signal of deteriorating financial health, and negative return on equity of -36.4% (sector average: -20.6%).
StockPik's composite Value Score for VACH is 25/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
VACH shows earnings growing at 117%.